<DOC>
	<DOCNO>NCT00392392</DOCNO>
	<brief_summary>This trial combine trastuzumab bevacizumab monoclonal antibody , ABI-007 carboplatin , neoadjuvant therapy previously untreated locally advanced breast cancer demonstrate HER2 gene amplification . It hop novel combination result increase pathologic response rate translate long term outcome improvement HER2 positive patient locally advance breast cancer .</brief_summary>
	<brief_title>Preoperative Bevacizumab Trastuzumab With ABI-007 Carboplatin HER2+ Breast Cancer</brief_title>
	<detailed_description>All eligible patient receive induction chemotherapy prior consideration primary surgical intervention . If surgical intervention deem best interest patient , patient go study time evaluation surgery . Upon completion chemotherapy surgery , ER + and/or PR + patient place Tamoxifen 20 mg/qd aromatase inhibitor . Induction preoperative therapy : - Bevacizumab - Trastuzumab - ABI-007 - Carboplatin Postoperative Adjuvant Therapy : - Bevacizumab - Trastuzumab</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Female patient histologically confirm adenocarcinoma breast inflammatory breast cancer Clinical stage T 14 , N 03 , M0 FISH+ HER2 gene amplify breast cancer 18 year old Normal cardiac function Performance status 02 Can receive prior chemotherapy disease receive chemotherapy cancer past 5 year . Previous diagnosis noninvasive breast cancer OK. Must adequate bone marrow , renal liver function . Pregnant lactating female allow . Preexisting peripheral neuropathy must equal less grade 1 Must archive tumor tissue tissue test . You study follow : History cardiac disease , New York Heart Association Class II great congestive heart failure Any heart attack , stroke TIAs within last 6 month serious arrhythmia need medication ; bleed diathesis coagulopathy . No prior investigational drug within last 30 day No prior trastuzumab bevacizumab therapy There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Breast Cancer</keyword>
</DOC>